

# Vaginal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/VADAC2E4CF8EEN.html>

Date: October 2022

Pages: 90

Price: US\$ 2,000.00 (Single User License)

ID: VADAC2E4CF8EEN

## Abstracts

Vaginal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vaginal Cancer - Drugs In Development, 2022, provides an overview of the Vaginal Cancer (Oncology) pipeline landscape.

Vaginal cancer is a rare cancer that occurs in vagina. Symptoms includes watery vaginal discharge, a lump or mass in vagina, painful urination, constipation and pelvic pain, vaginal bleeding. Risk factors include age, Smoking, HIV infection and vaginal intraepithelial neoplasia. Treatment includes surgery, radiation therapy and chemotherapy.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vaginal Cancer - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Vaginal Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Vaginal Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Vaginal Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and IND/CTA Filed stages are 7, 22, 8 and 1 respectively.

Vaginal Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Vaginal Cancer (Oncology).

The pipeline guide reviews pipeline therapeutics for Vaginal Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Vaginal Cancer (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Vaginal Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and

molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Vaginal Cancer (Oncology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Vaginal Cancer (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Vaginal Cancer (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

- Introduction
- Global Markets Direct Report Coverage
- Vaginal Cancer - Overview
- Vaginal Cancer - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Products under Development by Companies
- Vaginal Cancer - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Vaginal Cancer - Companies Involved in Therapeutics Development
- AstraZeneca Plc
- Beijing Kangle Guardian Biotechnology Co Ltd
- Beijing Kangleweishi Biotechnology Co Ltd
- Bristol-Myers Squibb Co
- Chengdu Institute of Biological Products Co Ltd
- Eisai Co Ltd
- F. Hoffmann-La Roche Ltd
- Gilead Sciences Inc
- Hookipa Pharma Inc
- ISA Pharmaceuticals BV
- Merck & Co Inc
- Merck KGaA
- Ology Bioservices Inc
- Ono Pharmaceutical Co Ltd
- PDS Biotechnology Corp
- Perseus Proteomics Inc
- Pionyr Immunotherapeutics Inc
- Precigen Inc
- Privo Technologies Inc
- RemeGen Co Ltd
- Shanghai Bovax Biotechnology Co Ltd
- Shanghai Zerun Biotechnology Co Ltd
- SinoCelltech Group Ltd
- SQZ Biotechnologies Co

Suzhou Neupharma Co Ltd

Transcenta Holding Ltd

Transgene SA

Turnstone Biologics Inc

Vaginal Cancer - Drug Profiles

adavosertib - Drug Profile

Product Description

Mechanism Of Action

bevacizumab - Drug Profile

Product Description

Mechanism Of Action

bintrafusp alfa - Drug Profile

Product Description

Mechanism Of Action

cisplatin - Drug Profile

Product Description

Mechanism Of Action

decitabine - Drug Profile

Product Description

Mechanism Of Action

disitamab vedotin - Drug Profile

Product Description

Mechanism Of Action

durvalumab - Drug Profile

Product Description

Mechanism Of Action

durvalumab + tremelimumab - Drug Profile

Product Description

Mechanism Of Action

HB-201 - Drug Profile

Product Description

Mechanism Of Action

HB-202 - Drug Profile

Product Description

Mechanism Of Action

HPV-16 E7 - Drug Profile

Product Description

Mechanism Of Action

human papillomavirus (9 valent) vaccine - Drug Profile

Product Description

Mechanism Of Action

human papillomavirus (9-valent) vaccine - Drug Profile

Product Description

Mechanism Of Action

human papillomavirus [serotypes 16, 18, 58] (trivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

human papillomavirus [serotypes 6, 11, 16, 18, 31, 33, 45, 52 and 58] (9-valent) vaccine - Drug Profile

Product Description

Mechanism Of Action

human papillomavirus [serotypes 6, 11, 16, 18] (quadrivalent) vaccine - Drug Profile

Product Description

Mechanism Of Action

human papillomavirus [serotypes 6,11,16,18,31,33,45,52,58,59 and 68] (11-valent) vaccine - Drug Profile

Product Description

Mechanism Of Action

human papillomavirus [serotypes 6,11,16,18,31,33,45,52,58] (9-valent) vaccine - Drug Profile

Product Description

Mechanism Of Action

ipilimumab + nivolumab - Drug Profile

Product Description

Mechanism Of Action

M-9241 - Drug Profile

Product Description

Mechanism Of Action

MEDI-0457 - Drug Profile

Product Description

Mechanism Of Action

nivolumab - Drug Profile

Product Description

Mechanism Of Action

NTO-1151 - Drug Profile

Product Description

Mechanism Of Action

Oncolytic Virus to Target E6 and E7 for Human Papillomavirus (HPV) Associated Solid

Tumors - Drug Profile  
Product Description  
Mechanism Of Action  
PDS-0101 - Drug Profile  
Product Description  
Mechanism Of Action  
peltopepimut-s - Drug Profile  
Product Description  
Mechanism Of Action  
pembrolizumab - Drug Profile  
Product Description  
Mechanism Of Action  
PPMX-T002 - Drug Profile  
Product Description  
Mechanism Of Action  
PRGN-2009 - Drug Profile  
Product Description  
Mechanism Of Action  
PRV-211 - Drug Profile  
Product Description  
Mechanism Of Action  
PY-159 - Drug Profile  
Product Description  
Mechanism Of Action  
PY-314 - Drug Profile  
Product Description  
Mechanism Of Action  
RX-208 - Drug Profile  
Product Description  
Mechanism Of Action  
SCT-1000 - Drug Profile  
Product Description  
Mechanism Of Action  
SQZ-AACs (Oncology) - Drug Profile  
Product Description  
Mechanism Of Action  
SQZ-APCs (Oncology) - Drug Profile  
Product Description  
Mechanism Of Action

tipapkinogene sovacivec - Drug Profile

Product Description

Mechanism Of Action

TST-005 - Drug Profile

Product Description

Mechanism Of Action

Vaginal Cancer - Dormant Projects

Vaginal Cancer - Product Development Milestones

Featured News & Press Releases

Sep 27, 2018: Vaccine, anti-PD1 drug show promise against incurable HPV-related cancers

Jun 17, 2015: GARDASIL9: New HPV vaccine approved in the European Union

Apr 01, 2015: Merck's HPV Vaccine, GARDASIL 9, now available in Canada

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer



## List Of Tables

### LIST OF TABLES

Number of Products under Development for Vaginal Cancer, 2022  
Number of Products under Development by Companies, 2022  
Number of Products under Development by Companies, 2022 (Contd..1)  
Products under Development by Companies, 2022  
Products under Development by Companies, 2022 (Contd..1)  
Products under Development by Companies, 2022 (Contd..2)  
Number of Products by Stage and Target, 2022  
Number of Products by Stage and Mechanism of Action, 2022  
Number of Products by Stage and Route of Administration, 2022  
Number of Products by Stage and Molecule Type, 2022  
Vaginal Cancer - Pipeline by AstraZeneca Plc, 2022  
Vaginal Cancer - Pipeline by Beijing Kangle Guardian Biotechnology Co Ltd, 2022  
Vaginal Cancer - Pipeline by Beijing Kangleweishi Biotechnology Co Ltd, 2022  
Vaginal Cancer - Pipeline by Bristol-Myers Squibb Co, 2022  
Vaginal Cancer - Pipeline by Chengdu Institute of Biological Products Co Ltd, 2022  
Vaginal Cancer - Pipeline by Eisai Co Ltd, 2022  
Vaginal Cancer - Pipeline by F. Hoffmann-La Roche Ltd, 2022  
Vaginal Cancer - Pipeline by Gilead Sciences Inc, 2022  
Vaginal Cancer - Pipeline by Hookipa Pharma Inc, 2022  
Vaginal Cancer - Pipeline by ISA Pharmaceuticals BV, 2022  
Vaginal Cancer - Pipeline by Merck & Co Inc, 2022  
Vaginal Cancer - Pipeline by Merck KGaA, 2022  
Vaginal Cancer - Pipeline by Ology Bioservices Inc, 2022  
Vaginal Cancer - Pipeline by Ono Pharmaceutical Co Ltd, 2022  
Vaginal Cancer - Pipeline by PDS Biotechnology Corp, 2022  
Vaginal Cancer - Pipeline by Perseus Proteomics Inc, 2022  
Vaginal Cancer - Pipeline by Pionyr Immunotherapeutics Inc, 2022  
Vaginal Cancer - Pipeline by Precigen Inc, 2022  
Vaginal Cancer - Pipeline by Privo Technologies Inc, 2022  
Vaginal Cancer - Pipeline by RemeGen Co Ltd, 2022  
Vaginal Cancer - Pipeline by Shanghai Bovax Biotechnology Co Ltd, 2022  
Vaginal Cancer - Pipeline by Shanghai Zerun Biotechnology Co Ltd, 2022  
Vaginal Cancer - Pipeline by SinoCelltech Group Ltd, 2022  
Vaginal Cancer - Pipeline by SQZ Biotechnologies Co, 2022  
Vaginal Cancer - Pipeline by Suzhou Neupharma Co Ltd, 2022

Vaginal Cancer - Pipeline by Transcenta Holding Ltd, 2022  
Vaginal Cancer - Pipeline by Transgene SA, 2022  
Vaginal Cancer - Pipeline by Turnstone Biologics Inc, 2022  
Vaginal Cancer - Dormant Projects, 2022

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Vaginal Cancer, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

## I would like to order

Product name: Vaginal Cancer Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/VADAC2E4CF8EEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/VADAC2E4CF8EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

